A leukemoid reaction (LR) is a reactive, non-malignant leukocytosis — classically defined as a WBC count >50,000/μL (some sources use ≥30,000/μL) with a neutrophil-predominant left shift — caused by an underlying physiologic stressor rather than a primary hematologic malignancy. [1-2] It constitutes approximately 0.59% of adult hospital admissions and carries a 38% in-hospital mortality driven by the severity of the underlying cause, not the leukocytosis itself. [3]
1. History
- Onset and duration of symptoms: acute vs. subacute; fever, chills, rigors
- Source-directed questioning: cough/dyspnea (pneumonia), abdominal pain (intra-abdominal abscess, C. difficile), dysuria, wound infection
- Trauma, surgery, burns, or recent procedures
- Hemorrhage history (GI bleed, postpartum hemorrhage)
- Medication use: corticosteroids, G-CSF/GM-CSF, lithium, β-agonists [2]
- Constitutional symptoms: unintentional weight loss, night sweats, fatigue, easy bruising (raises concern for malignancy) [4]
- Obstetric history if applicable (obstetric causes account for ~7% of LR) [3]
- Toxic exposures: ethylene glycol, carbon monoxide
2. Alarm Features
- WBC >100,000/μL — significantly raises probability of hematologic malignancy (CML, AML) over reactive cause [5-6]
- Persistent or rising WBC despite treatment of the presumed underlying cause [3]
- Prolonged LR (>1 day) — associated with 61.5% in-hospital mortality [3]
- Circulating blasts >5% on peripheral smear [7]
- Concurrent unexplained cytopenias (anemia, thrombocytopenia) [4][8]
- Hepatosplenomegaly or lymphadenopathy without infectious explanation
- Basophilia or eosinophilia out of proportion to clinical picture (suggests myeloproliferative neoplasm) [7]
- Signs of leukostasis: dyspnea, visual changes, headache, priapism, altered mental status [9]
- Signs of DIC: petechiae, mucosal bleeding, oozing from IV sites
3. Medications
Common contributors to leukocytosis
- Corticosteroids (demargination + marrow release; notably lack band forms) [2]
- G-CSF / GM-CSF (can cause WBC >50,000; pronounced left shift) [2]
- Lithium, β-agonists (theophylline, albuterol), tetracycline [2]
- Epinephrine (stress demargination)
Medications in management
- Antibiotics for underlying infection (prescribed in ~81% of LR cases) [3]
- No specific pharmacotherapy targets the leukemoid reaction itself — treatment is directed at the underlying cause
- If malignancy is suspected: hydroxyurea for cytoreduction pending definitive diagnosis [9-10]
Cautions
- Avoid RBC transfusion if WBC >100,000/μL until cytoreduction (risk of hyperviscosity) [11]
- Avoid empiric steroids before ruling out hematologic malignancy (may obscure diagnosis or cause tumor lysis in lymphoid malignancies) [12]
4. Diet
- No specific dietary triggers or recommendations for leukemoid reaction
- Adequate hydration is critical, particularly if there is concern for tumor lysis syndrome or sepsis
- NPO considerations if surgical pathology is suspected
5. Review of Systems
- Infectious: fever, chills, cough, sputum, dysuria, diarrhea (especially C. difficile — higher WBC significantly associated with positive C. difficile toxin) [3]
- Hematologic: easy bruising, bleeding, petechiae, fatigue, bone pain
- Constitutional: weight loss, night sweats, anorexia
- Pulmonary: dyspnea, hypoxia (leukostasis vs. pneumonia)
- Neurologic: headache, visual changes, confusion (leukostasis)
- GI: abdominal pain, melena, hematochezia (hemorrhage as cause)
- Obstetric: postpartum status, recent delivery complications
6. Collateral History and Family History
- Prior CBC values (baseline WBC, trajectory)
- Recent hospitalizations, surgeries, or infections
- History of malignancy (solid tumors — lung, stomach, breast — can cause paraneoplastic LR) [2]
- Family history of hematologic malignancies or myeloproliferative neoplasms
- Down syndrome in pediatric patients (associated with transient myeloproliferative disorder and exaggerated leukemoid responses) [2][13]
- Social history: smoking (chronic leukocytosis), occupational exposures
7. Risk Factors
- Severe infection/sepsis — most common cause (~48%) [3]
- Advanced age (median age 75 years in one large cohort) [3]
- Ischemia/physiologic stress (~28%) [3]
- Solid organ malignancy (paraneoplastic G-CSF production — lung, GI, breast) [1-2]
- Severe hemorrhage or acute hemolysis [1]
- Chronic inflammatory conditions (rheumatoid arthritis, inflammatory bowel disease) [2]
- Asplenia/hyposplenia [2]
- Smoking, obesity [4]
- Neonatal/premature status (1.3% incidence in NICU patients) [14]
- Down syndrome (trisomy 21) [2]
8. Differential Diagnosis
The critical clinical task is distinguishing a reactive leukemoid reaction from a primary hematologic malignancy: [1][7]
- Chronic myeloid leukemia (CML) — the most important cannot-miss diagnosis; distinguished by Philadelphia chromosome (BCR-ABL1), low LAP score, basophilia [2][15]
- Acute myeloid leukemia (AML) — circulating blasts, cytopenias, Auer rods [16]
- Chronic neutrophilic leukemia (CNL) — rare; CSF3R mutation; must exclude reactive causes [17]
- Myeloproliferative neoplasms (polycythemia vera, essential thrombocythemia, myelofibrosis) [18]
- Acute lymphoblastic leukemia — especially in pediatric patients with WBC >50,000 [8]
- Juvenile myelomonocytic leukemia (JMML) — in infants/young children [13]
- Transient abnormal myelopoiesis — neonates with trisomy 21 [13]
Distinguishing features favoring LR over malignancy
- Identifiable infectious/inflammatory trigger
- Toxic granulation, Döhle bodies, cytoplasmic vacuoles on smear [2][7]
- High/normal LAP score (low in CML) [2][19]
- Absence of Philadelphia chromosome / BCR-ABL1 [2][15]
- Orderly maturation on bone marrow exam [2]
- Elevated CRP (low CRP with high WBC favors malignancy in children) [8]
9. Past Medical History
- Prior hematologic abnormalities or known myeloproliferative disorder
- History of solid organ malignancy (paraneoplastic leukocytosis)
- Splenectomy or functional asplenia
- Chronic infections (TB, osteomyelitis, empyema) [2]
- Autoimmune/inflammatory conditions
- Prior episodes of extreme leukocytosis
- Diabetic ketoacidosis (reported trigger) [20]
10. Physical Exam
- Vitals: fever, tachycardia, hypotension (sepsis); tachypnea, hypoxia (pneumonia, leukostasis)
- HEENT: gingival hyperplasia (AML), oral ulcers, fundoscopic exam for papilledema/retinal hemorrhages (leukostasis)
- Lymph nodes: diffuse lymphadenopathy (malignancy)
- Abdomen: splenomegaly (CML, myelofibrosis), hepatomegaly; tenderness localizing infection
- Skin: petechiae, purpura, ecchymoses (thrombocytopenia/DIC); leukemia cutis; wound infections
- Lungs: consolidation (pneumonia/pleuropneumonia — most common cause in pediatric LR) [8]
- Neurologic: focal deficits, altered mental status (leukostasis, CNS hemorrhage)
- Musculoskeletal: bone tenderness (marrow infiltration)
11. Lab Studies
Initial workup
- CBC with manual differential and peripheral blood smear — the single most important initial test [4][7]
- CMP, LDH, uric acid (elevated in malignancy and tumor lysis)
- CRP / procalcitonin (elevated CRP supports reactive cause; low CRP with high WBC raises malignancy concern) [8][21]
- Blood cultures, urine culture, stool C. difficile testing as indicated [3]
- Coagulation studies (DIC screen)
- Lactate (sepsis evaluation)
To distinguish from malignancy
- Leukocyte alkaline phosphatase (LAP): high/normal in LR, low/absent in CML [2][19][22]
- BCR-ABL1 by FISH or RT-PCR: essential to exclude CML [15][18]
- Flow cytometry if blasts or abnormal lymphocytes are present [7]
- Bone marrow biopsy if malignancy cannot be excluded [7][18]
Expected findings in LR
- Neutrophil-predominant leukocytosis with left shift (bands, metamyelocytes, myelocytes) [2]
- Toxic granulation, Döhle bodies, cytoplasmic vacuoles [2]
- Elevated CRP/ESR
- Normal or elevated platelet count (thrombocytopenia suggests malignancy) [8]
12. Imaging
- Chest X-ray: first-line; pneumonia is the most common infectious cause, especially pleuropneumonia in children [8]
- CT chest/abdomen/pelvis: if occult infection, abscess, or solid tumor is suspected
- CT head: if neurologic symptoms suggest leukostasis or CNS hemorrhage
- Ultrasound: assess spleen size (splenomegaly favors myeloproliferative neoplasm); evaluate for intra-abdominal abscess
- Imaging is unnecessary if a clear infectious source is identified and the patient is responding to treatment
13. Special Tests
- Peripheral blood smear review — the cornerstone of initial evaluation; look for blast cells, dysplasia, basophilia, monomorphic populations [7]
- LAP score — historically the key differentiator (high in LR, low in CML), though less commonly used since molecular testing became available [19]
- BCR-ABL1 FISH/RT-PCR — gold standard to exclude CML [15][23]
- Flow cytometry — if blasts or atypical cells are identified
- Bone marrow aspirate and biopsy — indicated when malignancy cannot be excluded; shows orderly maturation in LR vs. clonal proliferation in malignancy [2][7]
- Myeloid mutation panel (NGS) — JAK2, CALR, MPL for myeloproliferative neoplasms; CSF3R for chronic neutrophilic leukemia [18]
- A machine learning algorithm using demographic and lab data has shown 96% sensitivity and 95.9% specificity for distinguishing myeloid malignancies from LR [5]
14. ECG
- Not routinely indicated for leukemoid reaction itself
- Obtain ECG if:
- Sepsis or hemodynamic instability
- Concern for leukostasis with cardiac involvement
- Hyperkalemia (tumor lysis syndrome)
- Baseline before initiating chemotherapy if malignancy is confirmed
15. Assessment
A leukemoid reaction is a marker of severe underlying disease, not a disease entity itself. The prognosis is determined by the underlying etiology: [1][3]
- Infection is the most common cause (48%), followed by ischemia/stress (28%), inflammation (7%), and obstetric causes (7%) [3]
- Median duration is 1 day, but prolonged LR (>1 day) carries 61.5% mortality [3]
- In-hospital mortality is 38% overall; independent predictors of death include age, infectious diagnosis (OR 2.6), and sepsis (OR 3.8) [3]
- In adults, a 6-fold increase in 12-month mortality has been observed in patients with LR compared to those with myeloid malignancies, reflecting the severity of the underlying conditions [5]
- In children, LR is associated with longer hospital stays but not increased mortality [8]
16. Treatment Plan
There is no specific treatment for leukemoid reaction — management is directed entirely at the underlying cause: [1][24]
- Sepsis/infection: aggressive fluid resuscitation, broad-spectrum antibiotics, source control; antibiotics were prescribed in 81% of LR cases [3]
- Hemorrhage: transfusion, surgical hemostasis
- Inflammatory conditions: disease-specific anti-inflammatory therapy
- Drug-induced: discontinue offending agent (G-CSF, steroids)
- Malignancy-associated (paraneoplastic): treat the underlying tumor
If malignancy cannot be excluded
- Hydroxyurea for cytoreduction while awaiting definitive diagnosis [9-10]
- Urgent hematology/oncology consultation
- IV hydration and allopurinol/rasburicase for tumor lysis prophylaxis if malignancy is suspected [12]
- Avoid RBC transfusion if WBC >100,000/μL [11]
The leukocytosis itself typically resolves spontaneously once the underlying cause is treated. [24]
17. Disposition
Admission criteria
- Sepsis or hemodynamic instability
- WBC >50,000/μL without a clear reactive cause
- Any concern for hematologic malignancy (blasts on smear, unexplained cytopenias)
- Signs of leukostasis (respiratory distress, neurologic symptoms)
- Need for IV antibiotics or surgical source control
- Prolonged LR (>1 day) given the high associated mortality [3]
Observation
Discharge criteria
- Clear reactive etiology identified and treated
- Downtrending WBC
- Malignancy excluded or hematology follow-up arranged
- Hemodynamically stable, tolerating PO
Specialist consultation triggers
- Hematology/oncology: if malignancy cannot be excluded, blasts on smear, WBC >100,000/μL, or persistent unexplained leukocytosis [4]
- Infectious disease: complex or occult infections
- Surgery: if surgical source control is needed
18. Follow Up / Return Precautions
- Repeat CBC within 48–72 hours to confirm downtrending WBC after treatment initiation
- If discharged, follow up within 1 week with repeat CBC and clinical reassessment
- Hematology follow-up if bone marrow biopsy or molecular testing is pending
Return precautions — instruct patients to return for
- Recurrent or worsening fever
- New bleeding, bruising, or petechiae
- Worsening fatigue, dyspnea, or confusion
- Unintentional weight loss or drenching night sweats
Expected course: WBC typically normalizes within days once the underlying trigger is addressed. Failure to normalize should prompt re-evaluation for occult infection, malignancy, or alternative diagnosis. [24]
The following algorithm outlines the systematic evaluation of leukocytosis, including when to suspect malignancy versus a reactive process:
References
1. An Update on the Etiology and Diagnostic Evaluation of a Leukemoid Reaction. — Sakka V, Tsiodras S, Giamarellos-Bourboulis EJ, Giamarellou H. European Journal of Internal Medicine. 2006.
2. White Blood Cells 1: Non-Malignant Disorders. — Stock W, Hoffman R. Lancet. 2000.
3. Leukemoid Reaction: Spectrum and Prognosis of 173 Adult Patients. — Potasman I, Grupper M. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2013.
4. Evaluation of Patients With Leukocytosis. — Riley LK, Rupert J. American Family Physician. 2015.
5. A Predictive Algorithm for Discriminating Myeloid Malignancies and Leukemoid Reactions. — Iyengar V, Meyer A, Stedman E, et al. The American Journal of Medicine. 2024.
6. Leukemia: What Primary Care Physicians Need to Know. — Gbenjo JTC, McCrary GLM, Wilson SE. American Family Physician. 2023.
7. Malignant or Benign Leukocytosis. — George TI. Hematology. American Society of Hematology. Education Program. 2012.
8. Leukemoid Reaction in the Pediatric Population: Etiologies, Outcome, and Implications. — Hoofien A, Yarden-Bilavski H, Ashkenazi S, Chodick G, Livni G. European Journal of Pediatrics. 2018.
9. Approach to Hyperleukocytosis and Leukostasis-Inpatient Management Strategies. — Baral MR, Bhandari S. Journal of Hospital Medicine. 2026.
10. Chronic Myeloid Leukemia. — Updated 2025-07-16. National Comprehensive Cancer Network.
11. Pediatric Acute Lymphoblastic Leukemia. — Updated 2025-08-11. National Comprehensive Cancer Network.
12. Tumor Lysis Syndrome. — Bociek RG, Lunning M. The New England Journal of Medicine. 2025.
13. Too Many White Cells-Tam, JMML, or Something Else?. — Satty A, Stieglitz E, Kucine N. Hematology. American Society of Hematology. Education Program. 2023.
14. Incidence, Significance, and Kinetic Mechanism Responsible for Leukemoid Reactions in Patients in the Neonatal Intensive Care Unit: A Prospective Evaluation. — Calhoun DA, Kirk JF, Christensen RD. The Journal of Pediatrics. 1996.
15. Chronic Myeloid Leukaemia. — Cortes J, Pavlovsky C, Saußele S. Lancet. 2021.
16. Acute Myeloid Leukaemia. — DiNardo CD, Erba HP, Freeman SD, Wei AH. Lancet. 2023.
17. Chronic Neutrophilic Leukaemia and Plasma Cell-Related Neutrophilic Leukaemoid Reactions. — Bain BJ, Ahmad S. British Journal of Haematology. 2015.
18. Myeloproliferative Neoplasms. — Updated 2026-01-22. National Comprehensive Cancer Network.
19. Leukocyte Alkaline Phosphatase. — Okun DB, Tanaka KR. American Journal of Hematology. 1978.
20. Leukemoid Reaction in a Pediatric Patient With Diabetic Ketoacidosis. — Gonzalez LK, Malhotra S, Levine M, Jacobson-Dickman E. Pediatric Emergency Care. 2017.
21. Leukemoid Reaction With Severe Thrombocytopenia in a Dying Patient: A Case Report and Literature Review. — Hongwei H. The Journal of International Medical Research. 2021.
22. Leucocyte Alkaline Phosphatase Identifies Terminally Differentiated Normal Neutrophils and Its Lack in Chronic Myelogenous Leukaemia Is Not Dependent on P210 Tyrosine Kinase Activity. — Dotti G, Garattini E, Borleri G, et al. British Journal of Haematology. 1999.
23. Section E6.1-6.6 of the American College of Medical Genetics and Genomics (ACMG) Technical Laboratory Standards: Cytogenomic Studies of Acquired Chromosomal Abnormalities in Neoplastic Blood, Bone Marrow, and Lymph Nodes. — Akkari Y, Baughn LB, Kim A, et al. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 2024.
24. Two Cases of Leukemoid Reaction in Premature Infants Caused by Fetal Inflammatory Response Syndrome. — Feng MT, Ji Q, Liu DD, Xu W. BMC Pediatrics. 2024.